White House makes deal with Eli Lilly, Novo Nordisk to lower weight loss drug prices and begin Medicare coverage

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

GLP-1 receptor agonists—the class of drugs behind Ozempic, Wegovy, and Mounjaro—may do more than regulate blood sugar and weight.

November 21, 2025

Vol.51 No.43

Clinical Roundup

One in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes, or another condition, KFF poll finds

About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a KFF Health Tracking Poll finds.

November 21, 2025

Vol.51 No.43

Conversation with The Cancer Letter Regulatory News

Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director

Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.

Trump signs CR that funds government through Jan. 30, ending the longest shutdown in U.S. history

On the evening of Nov. 12, President Donald Trump signed a continuing resolution that officially ended the 43-day-long U.S. government shutdown that began on Oct. 1.

Trump administration and Cornell reach agreement to restore federal research funding

Cornell University has come to an agreement with the Trump administration that will unfreeze the university’s more than $250 million in interrupted federal research funding and “protect Cornell’s students from violations of federal civil rights laws, including from discrimination based on race, sex, or national origin, and promote America’s hardworking farming and rural communities” following accusations of antisemitism and discrimination in admissions.

November 14, 2025

Vol.51 No.42

By Jacquelyn Cobb and Claire Marie Porter

Cancer Policy

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

FDA announced six additional awardees under the Commissioner’s National Priority Voucher pilot program, which aims to accelerate review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, Oct. 24, June 20, 2025).

November 07, 2025

Vol.51 No.41

By Jacquelyn Cobb

White House makes deal with Eli Lilly, Novo Nordisk to lower weight loss drug prices and begin Medicare coverage

YOU MAY BE INTERESTED IN

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

One in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes, or another condition, KFF poll finds

Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director

Trump signs CR that funds government through Jan. 30, ending the longest shutdown in U.S. history

Trump administration and Cornell reach agreement to restore federal research funding

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

Renew today!

Subscriber content

Never miss an issue!

Login